NCT03589729View on ClinicalTrials.gov

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts 10 Percent or More of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic SyndromeMyeloid SarcomaMyeloproliferative NeoplasmPhiladelphia Chromosome Positive
Interventions
DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexrazoxane Hydrochloride

Given IV

DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Idarubicin

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER